Studies on Derivation of Transcobalamin III from Granulocytes ENHANCEMENT BY LITHIUM AND ELIMINATION BY FLUORIDE OF IN VITRO INCREMENTS IN VITAMIN B<sub>12</sub>-BINDING CAPACITY

J. M. Scott; F. J. Bloomfield; R. Stebbins; V. Herbert

doi:10.1172/JCI107543

Studies on Derivation of Transcobalamin III from Granulocytes ENHANCEMENT BY LITHIUM AND ELIMINATION BY FLUORIDE OF IN VITRO INCREMENTS IN VITAMIN B₁₂-BINDING CAPACITY

J. M. Scott, F. J. Bloomfield, R. Stebbins, and V. Herbert

Published January 1, 1974 - More info

View PDF

Abstract

Unsaturated vitamin B₁₂-binding capacity (UBBC) of human serum is not reproducibly measurable because it increases variably in vitro in relation to time, temperature, and, in the case of plasma, anticoagulant present before removal of cells. This variable increase proved to be due to variable release in vitro of transcobalamin III (TC III) from granulocytes. UBBC increase was greatest (up to fourfold normal levels) in the presence of lithium, which is the heparin salt used in many laboratories doing UBBC studies. In vitro increase was least when blood was collected in EDTA at 0°C and immediately centrifuges at 0°C (T₀ sample); results equivalent to T₀ were obtained at room temperature even after several hours delay when 47 mM fluoride was present; either cold temperature or 47 mM fluoride appeared to prevent TC III release from granulocytes. The measured levels of the three transcobalamins with T₀ methods of collection, which presumably reflect most closely the in vivo circulating levels, suggest that TC I and TC III in normal plasms are of the same order of magnitude and together normally comprise less than 10% of the UBBC.

Approximately 90% of the UBBC content of sonicates of peripheral blood granulocytes and of bone marrow aspirates of normal individuals appears to be TC III, with the rest being TC I. Thus, normal myelocytes, like normal granulocytes, appear to contain mainly TC III. No TC II was present in any of the sonicates.

The general practice in most laboratories has been to determine serum UBBC. Because in vitro increments of up to 119% were found to occur in serum, this practice should be replaced by collection using methods that prevent such increments. Blood collected in EDTA-47 mM NaF had a stable, reproducible UBBC with no significant in vitro increment with time.

EDTA-NaF UBBC was 640±168 (range 380-921 pg B₁₂ bound/ml plasma) for 12 normal adult men and 809±232 (range 505-1208) for normal adult women. It presumably approximates circulating UBBC and is substantially below the serum UBBC mean of 935±262 (range 611-1506 for the same 12 men) and 1273±355 (range 811-2306 for the same 10 women).